Misplaced Pages

Potrasertib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)

Pharmaceutical compound
Potrasertib
Clinical data
Other namesIMP7068
Identifiers
IUPAC name
  • 7-(2,6-dichlorophenyl)-12-anilino]-2,5,7,11,13-pentazatricyclotrideca-1(13),5,9,11-tetraen-8-one
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC28H30Cl2N8O
Molar mass565.50 g·mol
3D model (JSmol)
SMILES
  • C1CN(C(N1C)C)C2=C(C=C(C=C2)NC3=NC=C4C(=N3)N5CCN=C5N(C4=O)C6=C(C=CC=C6Cl)Cl)C
InChI
  • InChI=InChI=1S/C28H30Cl2N8O/c1-16-12-19(8-9-23(16)36-14-17(2)35(4)18(3)15-36)33-27-32-13-20-25(34-27)37-11-10-31-28(37)38(26(20)39)24-21(29)6-5-7-22(24)30/h5-9,12-13,17-18H,10-11,14-15H2,1-4H3,(H,32,33,34)/t17-,18+
  • Key:BNVDJVMTLDUCGH-HDICACEKSA-N

Potrasertib is an investigational new drug that is being evaluated by IMPACT Therapeutics for the treatment of advanced solid tumors. It is oral inhibitor of WEE1 kinase, a key regulator of cell cycle checkpoints.

References

  1. "IMP 7068". AdisInsight. Springer Nature Switzerland AG.
  2. Wang Z, Li W, Li F, Xiao R (January 2024). "An update of predictive biomarkers related to WEE1 inhibition in cancer therapy". Journal of Cancer Research and Clinical Oncology. 150 (1): 13. doi:10.1007/s00432-023-05527-y. PMC 10794259. PMID 38231277.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: